WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019:
Cantor Fitzgerald Global Healthcare Conference – New York
Friday, October 4, 2019, 1:10 PM ET
Presentation: William H. Collier
Chardan Genetic Medicines Conference – New York
Monday, October 7, 2019, 8:00 AM ET
Fireside Chat: William H. Collier and Dr. Gaston Picchio
Live webcasts of the presentations can be accessed through the Investors section of Arbutus’ website at www.arbutusbio.com. A replay of the webcasts will be available for 90 days following the live presentations.
Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
William H. Collier
President and CEO
Investor Relations Consultant